Akoya Biosciences (NASDAQ:AKYA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Akoya Biosciences (NASDAQ:AKYA) posted its quarterly earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02), Zacks reports. Akoya Biosciences had a negative net margin of 66.77% and a negative return on equity of 162.99%.

Akoya Biosciences Trading Up 4.0 %

AKYA stock traded up $0.06 during midday trading on Monday, hitting $1.56. The stock had a trading volume of 344,100 shares, compared to its average volume of 778,988. The firm has a market cap of $77.33 million, a PE ratio of -1.32 and a beta of 1.32. The company has a debt-to-equity ratio of 5.62, a current ratio of 2.75 and a quick ratio of 1.85. Akoya Biosciences has a 12-month low of $1.43 and a 12-month high of $5.16. The company’s 50-day moving average price is $2.34 and its 200 day moving average price is $2.53.

Institutional Trading of Akoya Biosciences

An institutional investor recently raised its position in Akoya Biosciences stock. Bank of America Corp DE lifted its holdings in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 39.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,092 shares of the company’s stock after acquiring an additional 8,258 shares during the quarter. Bank of America Corp DE owned about 0.06% of Akoya Biosciences worth $67,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 79.42% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on AKYA shares. Canaccord Genuity Group downgraded Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Piper Sandler downgraded Akoya Biosciences from an “overweight” rating to a “neutral” rating and set a $2.40 price objective for the company. in a research report on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.98.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.